Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery team in the final of the 5th National RSC/SCI Retrosynthesis Competition

A team of Sygnature Discovery chemists has made it to the final of the 5th National RSC/SCI Retrosynthesis Competition in London on 16th March 2018.

This prestigious event will showcase the calibre of UK chemists from both industry and academia and provide a platform for them to demonstrate their retrosynthetic and forward synthetic prowess.  For many years, the UK has produced high calibre synthetic organic chemists, so the Sygnature team – known as “Mannich Black” – will be fighting it out with the creme de la creme of UK-based chemists.

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise.  Private equity-backed, Sygnature undertakes integrated drug discovery programmes for pharmaceutical and biotech companies located around the world.  Since 2011, 11 compounds invented at Sygnature for its clients have entered clinical trials (Phases I and II).

Sygnature Discovery’s chemistry department employs 120 medicinal/synthetic chemists (80% with PhDs), making it one of the largest and most experienced chemistry departments in the UK pharmaceutical sector.

Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.